Company: IXHL
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001213900-25-092837
Chunk: 956

Company: Incannex Healthcare Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 8
Chunk 956
---
.15 
  
    The loss and weighted average number of shares of common stock used in the calculation of basic loss per share is as follows: 

    Total comprehensive loss for the year (in thousands) 
     (46,677) 
     (18,536)
  
    - Weighted average number of shares of common stock (number) 
     34,454,269  
     16,164,338 

The Company notes that the diluted loss per share
is the same as basic loss per share.

Note 16 -Related Party Transactions

There were no amounts payable to any related parties
as of June 30, 2025 and 2024.

Note 17 - Subsequent Events

ATM Program Increase

On July 24, 2025, the Company filed a prospectus
supplement to increase the capacity of its ATM by up to an additional $100 million. While this filing increases the available capacity
under the ATM, the Company is under no obligation to issue any share of its common stock pursuant to the program. The expanded facility
is intended to enhance the Company’s financial flexibility, providing an efficient mechanism to access capital if, and when, deemed
appropriate. Any utilisation of the ATM will be at the discretion of the Company, taking into account prevailing market conditions and
strategic priorities.

As previously disclosed,
the ATM is conducted pursuant to the Amended and Restated Sales Agreement, by and among the Company and the Sales Agents. Accordingly,
pursuant to the prospectus supplement, the amount of shares of the Company’s common stock that the Company may issue under the Amended
and Restated Sales Agreement has been increased by up to an aggregate of $100 million of shares of the Company’s common stock. There
can be no assurance that the Sales Agents will be able to complete future placements pursuant to the Amended and Restated Sales Agreement,
even if instructed to do so. The number of shares of the Company’s common stock that the Company may ultimately sell under the Amended
and Restated Sales Agreement will fluctuate based on a number of factors, including the market price of its common stock during the sales
period, the limits it may set in any instruction to sell shares of its common stock, and the demand for its common stock during an applicable
sales period.

F-22

Item 9. Changes in and Disagreements with Accountants on Accounting
and Financial Disclosure

None.

Item 9A. Controls and